Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut

Bach, S P, Williamson, S E, O'Dwyer, S T, Potten, C S and Watson, A J M ORCID: https://orcid.org/0000-0003-3326-0426 (2006) Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut. British Journal of Cancer, 95 (1). pp. 35-41. ISSN 0007-0920

Full text not available from this repository.

Abstract

Pyrrolidinedithiocarbamate (PDTC) enhanced the activity of 5-fluorouracil (5-FU) in a colorectal cancer xenograft model. Pyrrolidinedithiocarbamate also reduced gastrointestinal toxicity associated with 5-FU therapy in large but not small bowel. We sought to clarify the basis of this differential enteric toxicity. Apoptosis and mitosis were assessed on a cell positional basis in small and large intestinal crypts of p53 wild-type (+/+) and p53 null (-/-) mice 6, 12, 24, 36, 48 and 72 h after the administration of high (200 mg kg(-1)) or low (40 mg kg(-1)) dose 5-FU+/-250 mg kg(-1) PDTC. Regimens were chosen to model a single human dose and a weekly schedule. The effects of another antioxidant N-acetylcysteine (NAC) were also investigated. Large intestinal crypts affect apoptosis purely by p53-dependent mechanisms, whereas small intestinal crypts are able to initiate both p53-dependent and -independent pathways following treatment with 5-FU. Pyrrolidinedithiocarbamate and NAC antagonised p53-dependent but potentiated p53-independent apoptotic activity. Consequently, the proportion of surviving clonogens increased in the large but not in the small intestine. Regional availability of p53-dependent and -independent apoptotic pathways in small and large intestine together with separate modulation of these pathways by antioxidants explains the different regional enterotoxicity following 5-FU therapy.

Item Type:	Article
Uncontrolled Keywords:	animals,antioxidants,apoptosis,colorectal neoplasms,dose-response relationship, drug,drug administration schedule,drug antagonism,drug synergism,fluorouracil,intestinal mucosa,intestine, large,intestine, small,mice,mice, knockout,mitosis,organ specificity,pyrrolidines,thiocarbamates,time factors,tumor suppressor protein p53,xenograft model antitumor assays,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Depositing User:	Rhiannon Harvey
Date Deposited:	14 Jul 2011 08:17
Last Modified:	20 Aug 2023 00:37
URI:	https://ueaeprints.uea.ac.uk/id/eprint/33688
DOI:	10.1038/sj.bjc.6603224

Actions (login required)

View Item